Business
Biodesix Initiates Biomarker Study to Affirm Nodify XL2® Test’s Importance in Clinical Decision Making
Dr. Gerard A. Silvestri of Medical University of South Carolina Named Principal Investigator BOULDER, Colo.--(BUSINESS WIRE)-- Biodesix, Inc. (Nasdaq: BDSX),
About this update from Biodesix, Inc.
[{"type":"text","content":"\nDr. Gerard A. Silvestri of Medical University of South Carolina Named Principal Investigator\n\n BOULDER, Colo.--(BUSINESS WIRE)--\nBiodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, is proud to announce the launch and active recruitment of a first-in-class biomarker study aligned with the recommendations from the official 2018 American Thoracic Society (ATS) policy statement on the early detection of lung cancer. The Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules (ALTITUDE), titled “A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules,” is a randomized blinded controlled study with the objective of assessing how clinical decision making is impacted by the introduction of Nodify Lung test results into risk assessment. The study will focus on new, incidentally identified patients with lung nodules that are estimated to have low to moderate risk of lung cancer using the current standard of care.\n\nThe study is designed to generate key data to provide further support for a testing strategy that improves on the current standard of care and that significantly enhances guidelines. Biodesix has selected Dr. Gerard Silvestri, Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina, to lead this trial. Dr. Silvestri is an internationally recognized researcher in all aspects of lung cancer care but with focused expertise in the early detection, evaluation and management of pulmonary nodules.\n\n“I am excited to serve as principal investigator for the ALTITUDE trial, a study that I consider to be the first of its kind,” said Dr. Silvestri. “We expect the trial to demonstrate that having the results of the Nodify XL2 Lung tests will lead to patients with benign disease avoiding unnecessary and invasive procedures. I believe that it will establish a new standard for future biomarker studies for the early detection of lung cancer.”\n\nWith a total enrollment goal of 2,000 patients, Biodesix anticipates publishing interim results in 2022 and expects to complete the study in late 2023.\n\n“As a data-driven company, Biodesix is committed to continuing to study our tests and their impact on patients and the healthcare ...